Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies
Open Access
- 1 July 2016
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 2 (7) , 890-898
Abstract
With the US Preventive Services Task Force recommendation against routine prostate-specific antigen (PSA) screening for prostate cancer1 and conservative guidance from other national panels,2-4 the future of PSA screening is uncertain. The recently updated guidelines relied heavily on results from 2 large trials conducted in the United States and Europe.5-7 These results have been interpreted by some as demonstrating that PSA screening provides at most modest benefit, with unacceptable costs in terms of overdiagnosis and overtreatment.8,9 However, for a long-term horizon, the number of lives saved by screening is likely to be considerably higher and the fraction of overdiagnosed patients is likely to be considerably lower compared with those of the trials.10-13 Rather than rejecting screening, additional studies13,14 have recommended seeking more personalized (or “smarter”) screening strategies that preserve benefit while reducing harm. Unfortunately, these strategies are unlikely to be evaluated in randomized clinical trials owing to resource and logistic constraints. Therefore, we have used modeling to conduct simulated comparisons of candidate screening approaches.Keywords
This publication has 55 references indexed in Scilit:
- Radical Prostatectomy versus Observation for Localized Prostate CancerNew England Journal of Medicine, 2012
- The impact of PLCO control arm contamination on perceived PSA screening efficacyCancer Causes & Control, 2012
- Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesJournal of Clinical Epidemiology, 2011
- Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancerCancer, 2011
- Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate CancerJAMA, 2010
- Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlBiostatistics, 2010
- Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–RotterdamJNCI: Journal of the National Cancer Institute, 2010
- When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in OncologyJNCI: Journal of the National Cancer Institute, 2010
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Quantifying the role of PSA screening in the US prostate cancer mortality declineCancer Causes & Control, 2007